Hepatitis D study in Chinese patients
Part of Digestive system, Infections clinical trials.
This study looks at people in China who have hepatitis D, a liver infection. It aims to learn more about the disease and how it affects people, which may help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a positive test for hepatitis D virus (HDV) RNA.
- You must be able to sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at patient information (your health data) for adults who test positive for HDV. You may help researchers better understand HDV by allowing their team to collect and use your data.
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
This trial focuses on improving and standardizing how hepatitis delta is cared for in the Netherlands. To take part, you must have confirmed active hepatitis delta and be an adult.
This research study evaluates people with liver disease or at risk for liver disease, and compares them with healthy volunteers. The goal is to better understand liver disease and improve how doctors diagnose and treat it.
This study tests a new medicine called HH-1270 in healthy volunteers to see if it is safe and how the body handles it. It is the first time this drug is being tested in humans, and the results will help decide future studies in patients.
This trial is testing treatments for people with chronic hepatitis D, a serious liver infection. If you have antibodies to the hepatitis D virus (HDV), you may be able to join and help find better ways to manage this condition.
Hear when a new Hepatitis D trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.